Frederick Pei Li
|
WikiDoc Resources for Frederick Pei Li |
|
Articles |
|---|
|
Most recent articles on Frederick Pei Li Most cited articles on Frederick Pei Li |
|
Media |
|
Powerpoint slides on Frederick Pei Li |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Frederick Pei Li at Clinical Trials.gov Trial results on Frederick Pei Li Clinical Trials on Frederick Pei Li at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Frederick Pei Li NICE Guidance on Frederick Pei Li
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Frederick Pei Li Discussion groups on Frederick Pei Li Patient Handouts on Frederick Pei Li Directions to Hospitals Treating Frederick Pei Li Risk calculators and risk factors for Frederick Pei Li
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Frederick Pei Li |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Frederick Pei Li (born 1940) is an American physician.
Frederick Pei Li was born in Canton, China (Guangzhou), and raised in New York City where his parents operated a Chinese restaurant. He received a B.A. in physics from New York University, an M.D. from the University of Rochester, and M.A. in demography from Georgetown University. In 1967 he joined the Epidemiology Branch of the National Cancer Institute (NCI). He served for 24 years, mostly at the NCI's field station at the Dana-Farber Cancer Institute in Boston. In 1991, he became head of Dana-Farber's Division of Cancer Epidemiology and Control.
Currently, Dr. Li is Professor of Clinical Cancer Epidemiology at the Harvard School of Public Health, Professor of Medicine at the Harvard Medical School, and the Harry and Elsa Jiler American Cancer Society Clinical Research Professor. In 1996, Dr. Li was appointed by President Bill Clinton to NCI's National Cancer Advisory Board.
This is Li's presentation of himself and his work:
Research Interests : Molecular Epidemiology of Hereditary Cancers Recent data have established that the basic molecular defects in cancer are genetic changes that result in loss of normal cellular control mechanisms. Some of these mutations can be inherited through the germline. "I have been studying inherited susceptibility of cancer through affected families. The goal is to identify genes that are involved in cancer development".
"I was attracted to studies of cancer families because epidemiological studies show that virtually all cancers manifest a tendency to aggregate in families. Close relatives of a cancer patient are at increased risk of that neoplasm, and perhaps other forms of cancer. The excess site-specific cancer risk is exceptionally high for carriers of certain cancer genes, in whom the attack rate can approach 100 percent. In candidate cancer families, the possibility that clustering is on the basis of chance must be excluded through epidemiological studies that establish the presence of an excess cancer risk. Predisposed families are candidates for laboratory studies to identify the inherited susceptibility factors. These investigations have lead to the identification and isolation of human cancer genes, the tumor suppressor genes. These cancer genes are among more than 200 single-gene traits associated with the development of cancer. Approximately a dozen inherited susceptibility genes have been definitively identified, and many more are being sought. From studies of retinoblastoma and other rare cancers, important new information was generated about the fundamental biology of cancers that arise in many patients. Isolation of an inherited cancer susceptibility gene provides opportunities for presymptomatic testing of at-risk relatives. However, testing of healthy individuals also raise important issues regarding informed consent, confidentiality and potential for adverse psychological, social and economic effects."
"My colleagues and I are using families with inherited mutations in the p53 gene, which predisposes to breast cancer and diverse childhood cancers, as a model for developing a genetic testing program".